F10 and hemorrhagic disease: Besides correct phenotype and severity classification for hereditary bleeding disorders, testing also involves diagnosing acquired or treatment‐induced bleeding conditions, some of which are considered critical hemostasis tests (i.e., anti‐FXa activity for heparin/low molecular weight heparin [LMWH]).9